Shares of Inflarx NV (NASDAQ:IFRX) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $42.67.
IFRX has been the topic of a number of recent research reports. SunTrust Banks initiated coverage on Inflarx in a research report on Thursday, June 28th. They issued a “buy” rating and a $55.00 target price on the stock. Zacks Investment Research raised Inflarx from a “sell” rating to a “hold” rating in a research report on Thursday, June 28th. Raymond James initiated coverage on Inflarx in a research report on Thursday, June 28th. They issued an “outperform” rating and a $44.00 target price on the stock. Finally, BMO Capital Markets initiated coverage on Inflarx in a research report on Friday, July 13th. They issued an “outperform” rating and a $45.00 target price on the stock.
Shares of Inflarx stock opened at $34.32 on Friday. Inflarx has a 52-week low of $14.47 and a 52-week high of $42.83. The company has a market capitalization of $813.15 million and a P/E ratio of -11.67.
Inflarx (NASDAQ:IFRX) last announced its earnings results on Thursday, August 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.24. equities analysts expect that Inflarx will post -1.43 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in IFRX. Barclays PLC acquired a new position in shares of Inflarx during the 1st quarter worth approximately $144,000. Northern Trust Corp acquired a new position in shares of Inflarx during the 1st quarter worth approximately $228,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Inflarx during the 1st quarter worth approximately $367,000. Birchview Capital LP acquired a new position in shares of Inflarx during the 2nd quarter worth approximately $516,000. Finally, Millennium Management LLC acquired a new position in shares of Inflarx during the 2nd quarter worth approximately $1,916,000. 54.80% of the stock is currently owned by institutional investors and hedge funds.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Featured Story: Google Finance Portfolio
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.